PRE-MARKET | November 01, 2016 | $BP, $CMG, $CVX, $GILD, $X, $CMI, $TAP, $HLF, $COH, $PFE, $ICE #traders, #options

PRE-MARKET MOVERS

 

UPGRADES

 

DOWNGRADES

 

EARNINGS

 

Trending Social Alerts

 

Trending News Headlines

A federal probe of Alibaba’s books is far from dead — and it’s getting help from at least one insider. The Securities and Exchange Commission is working with one or more whistleblowers as it invest…

Pfizer Inc. announced today the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i). The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders. As a result, Pfizer has decided to discontinue the development program, including the two ongoing cardiovascular outcome studies.

Pfizer Inc. on Tuesday lowered its earnings outlook for the year and said it was ending the development of a drug in the massive cholesterol-treatment sector.

Pfizer Inc (PFE.N), the largest U.S. drugmaker, reported a quarterly adjusted profit that just missed analysts’ estimates, and the company shaved 4 cents off its 2016 earnings forecast after scrapping development of a cholesterol-lowering treatment.

This story is developing. Please check back for further updates.

Newspaper company Gannett has dropped its bid to buy Chicago Tribune publisher Tronc, ending a monthslong pursuit of its rival.

The owner of the USA Today is not buying the owner of the Chicago Tribune and the stocks are crashing.

Investor expectations will now present tough questions for the former Tribune Publishing, owner of The Los Angeles Times and Chicago Tribune.

Twenty years ago, procurement was a manual function driven largely by phone calls, faxes and handshakes. Then along came the Internet. And a company n

French drugmaker Sanofi stepped up its overhaul on Friday, putting its European generic drugs business up for sale and saying that a planned 3.5 billion euro ($3.8 billion) share buyback would not suppress its appetite for deals.

CARLSBAD, Calif. , Nov. 1, 2016 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive data from a Phase 2 placebo-controlled study evaluating IONIS-FXI Rx in patients with end-stage renal disease (ESRD) on hemodialysis. In this Phase 2 study patients treated with IONIS-FXI Rx achieved statistically significant, dose-dependent reductions in Factor XI activity. There were no clinically meaningful reductions in platelet levels and no treatment-related major or clinically relevant non-major bleeding events.

Technology News